Company intelligence / Profile preview

VESSL Therapeutics

Haifa, Haifa District, Israelvessltherapy.com ↗

Ownership: Private
Development stage: Phase 2

Overview

VESSL Therapeutics has completed two early-stage clinical trials demonstrating safety and initial efficacy of its cell/gene therapy products. The company raised $16M in Series AA funding to advance MGA into a larger Phase IIB trial for peripheral arterial disease, and MGG into a first-in-human study for hemodialysis patients. Their approach uses autologous vascular cells modified with angiogenic genes to promote new blood vessel growth or improve dialysis graft function.

Therapeutic areas: CardiovascularNephrology
Modalities: Cell therapyGene therapy
Industry: Biotech

Drug pipeline

1 asset

MultiGeneAngio

Partnerships

RunYoung Capital (financing round leader)

Beyond the preview

Go deeper on VESSL Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VESSL Therapeutics.

Explore the full profile